Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients
NCT ID: NCT00926224
Last Updated: 2010-11-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
300 participants
INTERVENTIONAL
2009-07-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FibroScan M and XL probes
Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient able to give written informed consent form
* Patient with a BMI superior or equal to 28kg/m²
* Patient scheduled to have a liver biopsy within 1 month after the enrollment or with a liver biopsy performed within 6 months before the enrollment.
* Patient for which abdominal ultrasound is technically possible
Exclusion Criteria
* Confirmed diagnosis and/or history of malignancy, or other terminal disease
* Patients with clinical ascites
* Pregnant women
* Patient with a BMI \< 28 kg/m²
* Patients with any active implantable medical device (such as pacemaker or defibrillator)
* Transplanted patient and patient with heart disease
* Refusal to undergo a liver biopsy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Echosens
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Echosens
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Calgary University Hospital
Calgary, Alberta, Canada
London University Hospital
London, Ontario, Canada
Toronto Western General Hospital
Toronto, Ontario, Canada
Toronto Liver Centre
Toronto, Ontario, Canada
Saint-Luc University
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M111
Identifier Type: -
Identifier Source: org_study_id